• 1
    Kasper C, Aledort L, Counts R et al. A more uniform measurement of factor VIII-inhibitors. Thromb Diath Haemorrh 1975; 34: 86972.
  • 2
    Biggs R, Bidwell E. A method for the study of antihaemophilic globulin inhibitors with reference to six cases. Br J Haematol 1959; 5: 37995.
  • 3
    Verbruggen B, Wessels H, Verbeek K, Polenewen R, Nóvakóva I. Frequency of inhibitors in haemophiliacs. The Lancet 1992; 339: 1301.
  • 4
    Verbruggen B, Novakova I, Wessels H et al. The Nijmegen modification of the Bethesda assay for factor VIII: C Inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 24751.
  • 5
    Verbruggen B, Dardikh M, Laros-van Gorkom B. Detecting and Quantifying Acquired Functional Inhibitors in Haemostasis. Quality in Laboratory Hemostasis and Thrombosis. First edition; edited by Steve Kitchen, John D Olsen, Eric Preston: Published by Wiley-Blackwelll Publishing Ltd, 2009.
  • 6
    Verbruggen B, Giles A, Samis J, Verbeek K, Mensink E, Novakova I. The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors. Thromb Haemost 2001; 86: 14359.
  • 7
    Meijer P, Verbruggen B. The between-laboratory variation of factor VIII inhibitor testing: The experience of the external quality assessment program of the ECAT foundation. Semin Thromb Hemost 2009; 35: 78693.
  • 8
    Favaloro EJ, Bonar R, Kershaw G, Mohammed S, Duncan E, Marsden K; (on behalf RCPA Haematology QAP Haemostasis Committee). Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia. Haemophilia 2010; 16: 66270.
  • 9
    Bonar RA, Favaloro EJ, Marsden K. External quality assessment of factor VIII inhibitor assays. Semin Thromb Hemost 2013; 39: 3206.
  • 10
    Favaloro EJ, Meijer P, Jennings I et al. Problems and solutions in laboratory testing for hemophilia. Semin Thromb Hemost 2013; 39: 81633.
  • 11
    Dardikh M, Albert T, Masereeuw R et al. Low-titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half-life after immune tolerance induction. J Thromb Haemost 2012; 10: 7068.
  • 12
    Hay CRM, DiMichele DM. The principal results of the international immune tolerance study: a randomized dose comparison. Blood 2012; 119: 133544.
  • 13
    Soucie JM, Miller CH, Kelly FM et al. A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. Haemophilia 2014; 20: 2307.
  • 14
    Miller CH, Platt SJ, Rice AS, Kelly F, Soucie JM, the Hemophilia Inhibitor Research Study Investigators. Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. J Thromb Haemost 2012; 10: 105561.
  • 15
    Miller CH, Rice AS, Boylan B et al. Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study (HIRS). J Thromb Haemost 2013; 11: 13009.